A prospective, phase III trial to evaluate the efficacy and safety of HIV vaccine [Biosantech] in patients with HIV infections

Trial Profile

A prospective, phase III trial to evaluate the efficacy and safety of HIV vaccine [Biosantech] in patients with HIV infections

Planning
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Mar 2016 New trial record
    • 15 Mar 2016 According to Biosantech media release, based on the results of its IIa trial (see CTP700229617), the company will put forward request for this phase III trial of its anti-HIV vaccine for an extensive evaluation during 2016. Subject to approval by the regulatory authorities and the results of this trial, an initial anti-HIV vaccine would be available from the H2 of 2018. The company intends to request a MAA for its anti-HIV vaccine in second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top